In the latest Gut Check podcast, Drs. Brian Lacy and Andree Koop talk about noncardiac chest pain, a common condition that often send patients to emergency departments or primary care and from there to the care of gastroenterologists.
In the latest Gut Check podcast, Drs. Brian Lacy and Andree Koop talk about noncardiac chest pain, a common condition that often send patients to emergency departments or primary care and from there to the care of gastroenterologists.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
Corticosteroids, proton pump inhibitors, and antidepressants were found to be associated with increased risks of contracting Clostrioides diffiicile infection, researchers reported.
Corticosteroids, proton pump inhibitors, and antidepressants were found to be associated with increased risks of contracting Clostrioides diffiicile infection, researchers reported.
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Dr Fontana recaps his presentation at Digestive Disease Week 2026 on advances in diagnosis and treatment for patients with MASLD and MASH, and the importance of collaboration among specialties as the numbers of patients with these conditions...
Data indicate that while overall mortality from colorectal cancer has declined over the past 30 years, the rate increased from 2013 to 2023 and may continue to rise through 2040.
Data indicate that while overall mortality from colorectal cancer has declined over the past 30 years, the rate increased from 2013 to 2023 and may continue to rise through 2040.
The update emphasizes that offering several validated screening options can improve adherence because “the most effective screening test is the one that the patient completes.”
The update emphasizes that offering several validated screening options can improve adherence because “the most effective screening test is the one that the patient completes.”
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
